XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC

This study investigates the efficacy and safety of XELOX chemotherapy combined with sintilimab and hyperbaric oxygen therapy (HBOT) as a first-line treatment for patients with Advanced or Metastatic gastric and gastroesophageal junction adenocarcinoma. The trial comprises two phases: a phase Ib study to determine the optimal HBOT regimen and assess safety and tolerability, followed by a phase II study to evaluate the overall response rate (ORR). Secondary outcomes include progression-free survival (PFS), disease control rate (DCR), 2-year disease-free survival (DFS), 2-year overall survival (O

Trial Details

NCT ID
NCT06742411
Phase
PHASE1 / PHASE2
Sponsor
West China Hospital
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • XELOX+Sintilimab+HBOT
Locations (sample)
  • Chengdu, Sichuan, China|30.66667,104.06667
  • Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

  • Diagnosis: Histologically or cytologically confirmed adenocarcinoma of the stomach or gastroesophageal junction (including signet ring cell carcino…
  • Disease status: The presence of metastatic disease, attributable to either recurrence or distant dissemination, was established through a combinati…
  • Survival Expectancy: Predicted to live more than 3 months. 4.Age: 18-75 years. 5.Prior treatments:
  • There are no previous antitumor treatments (chemotherapy, radiotherapy, targeted therapy, immunotherapy, interventional therapy, etc.).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →